OTCMKTS:PHGUF Pharming Group - PHGUF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. $1.03 0.00 (0.00%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.03▼$1.0350-Day Range$0.97▼$1.4552-Week Range$0.74▼$1.45VolumeN/AAverage Volume337 shsMarket Capitalization$671.98 millionP/E Ratio25.76Dividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest About Pharming Group (OTCMKTS:PHGUF) StockPharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.Read More Receive PHGUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGUF Stock News HeadlinesMarch 17, 2023 | americanbankingnews.comPharming Group (OTCMKTS:PHGUF) and LifeVantage (NASDAQ:LFVN) Critical AnalysisMarch 13, 2023 | finance.yahoo.comPharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcementMarch 21, 2023 | Press Reach (Ad)Stock Market UpdateThis stock is taking America by storm. Find out why it's trending right now. February 28, 2023 | finanznachrichten.dePharming Group N.V.: Notice of Full Year 2022 financial resultsFebruary 28, 2023 | finance.yahoo.comNotice of Full Year 2022 financial resultsFebruary 21, 2023 | finanznachrichten.dePharming Group N.V.: Pharming announces first patient enrolled in pediatric clinical trial of leniolisibJanuary 9, 2023 | finance.yahoo.comPharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 49% Above Its Share PriceDecember 19, 2022 | finance.yahoo.comPharming Group N.V.'s (AMS:PHARM) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?March 21, 2023 | Press Reach (Ad)Stock Market UpdateThis stock is taking America by storm. Find out why it's trending right now. December 15, 2022 | finance.yahoo.comPharming Highlights Interim Data From Rare Immune Deficiency StudyDecember 15, 2022 | finance.yahoo.comPharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionNovember 23, 2022 | finance.yahoo.comRecent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's WhyOctober 31, 2022 | finance.yahoo.comPharming Group N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsOctober 29, 2022 | seekingalpha.comPharming Group N.V. (PHGUF) Q3 2022 Earnings Call TranscriptOctober 12, 2022 | finance.yahoo.comPharming Group Notice of Q3 ResultsOctober 11, 2022 | finance.yahoo.comPharming submits a Marketing Authorisation Application to the European Medicines Agency for LeniolisibOctober 6, 2022 | finance.yahoo.comPharming's Leniolisib Goes Under Priority FDA Review For Rare Immune System DisorderSeptember 14, 2022 | reuters.comPharming Group NVAugust 6, 2022 | seekingalpha.comPharming Group N.V. 2022 Q2 - Results - Earnings Call PresentationAugust 4, 2022 | finance.yahoo.comPharming Group reports financial results for the first half of 2022August 2, 2022 | msn.comEMA committee grants accelerated assessment for Pharming Group’s leniolisibJuly 19, 2022 | morningstar.comPharming Group - Stock Quote PHGUFJune 2, 2022 | finance.yahoo.comPharming Group to present at Jefferies Healthcare Conference 2022May 4, 2022 | finance.yahoo.comPharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRAJanuary 6, 2022 | finanznachrichten.dePharming Group N.V.: Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in EuropeJanuary 6, 2022 | finance.yahoo.comPharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in EuropeOctober 28, 2021 | finance.yahoo.comPharming Group NV (PHGUF) to Report Q3 Results: What Awaits?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PHGUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGUF Company Calendar Last Earnings3/05/2015Today3/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PHGUF Previous SymbolOTC:PHGUF CUSIPN/A CIKN/A Webwww.pharming.com Phone(171) 524-7400Fax31-0-71-524-7445Employees277Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio25.76 Forward P/E RatioN/A P/E GrowthN/ANet Income$16 million Net Margins14.90% Pretax MarginN/A Return on Equity15.52% Return on Assets7.77% Debt Debt-to-Equity Ratio0.68 Current Ratio5.40 Quick Ratio4.68 Sales & Book Value Annual Sales$198.87 million Price / Sales3.38 Cash Flow$0.06 per share Price / Cash Flow16.96 Book Value$0.31 per share Price / Book3.32Miscellaneous Outstanding Shares652,410,000Free FloatN/AMarket Cap$671.98 million OptionableNot Optionable Beta1.10 Key ExecutivesSijmen de VriesChief Executive Officer & Executive DirectorMireille SandersChief Operations OfficerJeroen Henk WakkermanChief Financial OfficerRobert FriesenChief Scientific OfficerAnurag RelanChief Medical OfficerKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSAInnovivaNASDAQ:INVAKura OncologyNASDAQ:KURAPharming GroupNASDAQ:PHARPOINT Biopharma GlobalNASDAQ:PNTView All Competitors PHGUF Stock - Frequently Asked Questions How have PHGUF shares performed in 2023? Pharming Group's stock was trading at $1.1499 at the start of the year. Since then, PHGUF shares have decreased by 10.4% and is now trading at $1.03. View the best growth stocks for 2023 here. Are investors shorting Pharming Group? Pharming Group saw a decline in short interest during the month of February. As of February 28th, there was short interest totaling 2,709,800 shares, a decline of 16.4% from the February 13th total of 3,240,100 shares. Based on an average trading volume of 400 shares, the short-interest ratio is currently 6,774.5 days. View Pharming Group's Short Interest. How were Pharming Group's earnings last quarter? Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a trailing twelve-month return on equity of 15.52% and a net margin of 14.90%. What is Pharming Group's stock symbol? Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF." How do I buy shares of Pharming Group? Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pharming Group's stock price today? One share of PHGUF stock can currently be purchased for approximately $1.03. How much money does Pharming Group make? Pharming Group (OTCMKTS:PHGUF) has a market capitalization of $671.98 million and generates $198.87 million in revenue each year. The biotechnology company earns $16 million in net income (profit) each year or $0.04 on an earnings per share basis. How many employees does Pharming Group have? The company employs 277 workers across the globe. How can I contact Pharming Group? Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The official website for the company is www.pharming.com. The biotechnology company can be reached via phone at (171) 524-7400, via email at investor@pharming.com, or via fax at 31-0-71-524-7445. This page (OTCMKTS:PHGUF) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.